Crescent Biopharma (CBIO) Proxy filing summary

Voting matters and shareholder proposals

• Election of two Class II directors, Jonathan Violin, Ph.D., and Susan Moran, M.D., MSCE, for terms expiring at the 2029 Annual General Meeting or until a successor is elected or earlier departure.

• Additional business may be addressed if properly brought before the meeting or any adjournment.

Board of directors and corporate governance

• Board recommends voting in favor of the nominated Class II directors.

Shareholder rights and capital structure

• Shareholders are invited to vote virtually at the annual meeting scheduled for June 2, 2026, or online prior to the meeting.

• Proxy materials and annual report are available online, with options for paper or email copies upon request.